Patient selection. Of 1229 patients in the MCL Younger and Elderly trials, 675 were recruited by the GLSG. Reference pathology-certified MCL in 655 of these patients. Serum samples from 312 of these 655 patients could be analyzed for LRPAP1 autoantibodies.